Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

When renal allografts turn DARC.

Stephan Segerer1, Georg A Böhmig, Markus Exner

  • 1Medizinische Poliklinik, Klinikum Innenstadt der Universität, Pettenkoferstrasse 8a, 80336 Munich, Germany. stephan.segerer@lrz.uni-muenchen.de

Transplantation
|April 17, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donor bone marrow together with recipient regulatory T cells induces chimerism without irradiation in kidney transplantation.

Science translational medicine·2026
Same author

Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

The Banff 2024 Kidney Meeting Report: Rejection as a spectrum of phenotypes and focus on differential diagnostic reasoning.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

DARC and Anti-Duffy Antibodies in the Line of Fire: The Challenges in Pinpointing the Etiology of Microcirculation Inflammation to a Distinct Entity.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same author

Crovalimab Rescue Therapy in a Case With Genetic Complement Mediated Thrombotic Microangiopathy.

Kidney medicine·2026
Same author

International Kidney Paired Donation Programs: Evolution and Practices of 4 Large Collaborations.

Transplantation·2025
Same journal

Filtered or Fried? Rethinking Intraoperative Cell Salvage in Liver Transplantation.

Transplantation·2026
Same journal

Simultaneous Liver-kidney Versus Liver Transplantation Categorized by Pretransplant eGFR: Impact of the 2017 OPTN Policy.

Transplantation·2026
Same journal

Preformed Anti-DQ Alpha Donor-specific Antibodies and the Risk of Antibody-mediated Rejection After Kidney Transplantation.

Transplantation·2026
Same journal

People in Transplantation: Professor Nadey Hakim, MD, PhD, FRCS, FRCSGlas (Hon), FACS, President-Elect of The Transplantation Society.

Transplantation·2026
Same journal

IL-1 Receptor Blockade Modulates Inflammation During Sequential Perfusion in Ex Vivo Porcine Kidneys.

Transplantation·2026
Same journal

Regulatory T Cells Allosensitized Under the Blockade of CD80/CD86-CD28 Costimulation Prolonged Islet Allograft Survival.

Transplantation·2026
See all related articles

The Duffy antigen-receptor for chemokines (DARC) is upregulated in renal allograft rejection. DARC expression increases with both cellular and humoral rejection, particularly when both occur simultaneously.

Area of Science:

  • Nephrology
  • Immunology
  • Transplantation

Background:

  • The Duffy antigen-receptor for chemokines (DARC) is a chemokine-binding protein.
  • DARC is upregulated on peritubular capillaries (PTC) during cellular renal allograft rejection.
  • C4d deposition and inflammatory cell accumulation in PTC indicate humoral renal allograft rejection.

Purpose of the Study:

  • To evaluate DARC expression in different forms of human renal allograft rejection.
  • To investigate the role of DARC in inflammatory cell recruitment at the site of C4d deposition.
  • To correlate DARC expression with C4d deposition and rejection types.

Main Methods:

  • Immunohistochemistry was used to assess C4d deposition and DARC expression in 42 renal transplant biopsies.

Related Experiment Videos

  • Biopsies were categorized into C4d-negative (with/without cellular rejection) and C4d-positive (humoral rejection, with/without cellular rejection) groups.
  • Quantification of DARC-positive PTC per high-power field (HPF) was performed.

    • Main Results:

    • DARC expression was minimal in non-rejected kidneys.
    • Both cellular and humoral rejection significantly increased DARC-positive PTC numbers (9.7 and 8.7 vessels/HPF, respectively) compared to controls (2.6 vessels/HPF).
    • Combined humoral and cellular rejection showed the highest DARC expression (17.5 vessels/HPF).

    Conclusions:

    • This study is the first to show DARC induction at C4d deposition sites in humoral allograft rejection.
    • The findings suggest that DARC expression is induced by rejection processes.
    • Additive effects of humoral and cellular rejection on DARC expression imply distinct induction pathways.